Diabetes is a multi-factorial disorder that should be treated with multi-effective compounds. Here we describe the access to polyhydroxylated pyrrolidines, belonging to the D-gluco and D-galacto series, through aminocyclization reactions of two differentially protected D-xylo-hexos-4-ulose derivatives. The prepared compounds proved to inhibit both alpha-glucosidase, responsible for the emergence of hyperglycemic spikes, and aldose reductase, accountable for the development of abnormalities in diabetic tissues. Accordingly, they show the dual inhibitory profile deemed as ideal for diabetes treatment. Significantly, compound 17b reduced the process of cell death and restored the physiological levels of oxidative stress when tested in the phot...
Aldose reductase (ALR2), a NADPH-dependent reductase, is the first and rate-limiting enzyme of the p...
Objective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of ...
Aldose reductase (ALR2) has been the target of therapeutic intervention for over 40 years; first, fo...
Diabetes is a multi-factorial disorder that should be treated with multi-effective compounds. Here w...
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting long-term seconda...
Aldose reductase is a key enzyme in the development of long term diabetic complications and its inhi...
The aim of my PhD work was to design, synthesize and test novel heterocyclic compounds able to inhib...
Aldose reductase (AKR1B1), the key enzyme of the polyol pathway, plays a crucial role in the develop...
Background: Aldose reductase, the first enzyme of the polyol pathway, is the key determinant for th...
The results of recent clinical trials emphasise the importance of an improved glycaemic control in d...
© 2017 The Author(s). Glucokinase is one of the promising targets for glucose-lowering agents, and t...
Diabetes is often accompanied by several long-term complications such as neuropathy, nephropathy, re...
Designed multiple ligands (DMLs), developed to modulate simultaneously a number of selected targets ...
Previously studied inhibitors of aldose reductase were largely from two chemical classes, spirosucci...
International audienceEfforts to identify treatments for chronic diabetic complications have resulte...
Aldose reductase (ALR2), a NADPH-dependent reductase, is the first and rate-limiting enzyme of the p...
Objective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of ...
Aldose reductase (ALR2) has been the target of therapeutic intervention for over 40 years; first, fo...
Diabetes is a multi-factorial disorder that should be treated with multi-effective compounds. Here w...
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia resulting long-term seconda...
Aldose reductase is a key enzyme in the development of long term diabetic complications and its inhi...
The aim of my PhD work was to design, synthesize and test novel heterocyclic compounds able to inhib...
Aldose reductase (AKR1B1), the key enzyme of the polyol pathway, plays a crucial role in the develop...
Background: Aldose reductase, the first enzyme of the polyol pathway, is the key determinant for th...
The results of recent clinical trials emphasise the importance of an improved glycaemic control in d...
© 2017 The Author(s). Glucokinase is one of the promising targets for glucose-lowering agents, and t...
Diabetes is often accompanied by several long-term complications such as neuropathy, nephropathy, re...
Designed multiple ligands (DMLs), developed to modulate simultaneously a number of selected targets ...
Previously studied inhibitors of aldose reductase were largely from two chemical classes, spirosucci...
International audienceEfforts to identify treatments for chronic diabetic complications have resulte...
Aldose reductase (ALR2), a NADPH-dependent reductase, is the first and rate-limiting enzyme of the p...
Objective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of ...
Aldose reductase (ALR2) has been the target of therapeutic intervention for over 40 years; first, fo...